Author: Anna Smith

Takeda to evaluate Crescendo Biologics’ Humabodies

Crescendo Biologics has announced that Takeda is planning to evaluate the application of its recently licensed Humabodies, for the development of novel CAR-T therapeutics.

NHS winter figures encouraging ahead of ‘toughest days’

The NHS Confederation has said that the latest NHS winter figures are encouraging, but that the ‘toughest days may well come later’.

MHRA responds to consultation on Brexit no-deal proposals

In advance of the UK leaving the European Union on 29 March 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) has released a statement detailing its preparations for the event of a no-deal Brexit scenario.

NICE recommends Fasenra injection as asthma alternative

The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.

Sprycel combo gets FDA approval

The US Food and Drug Administration has approved the new treatment Sprycel for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with chemotherapy.